{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["DSP107","azacitidine"],["DSP107","azacitidine","venetoclax"]],"indication":"acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia","name":"NCT04937166","nct_id":"NCT04937166","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04937166. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.\n\nAzacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.\n\nPatients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards.","label":"DSP107 in combination with azacitidine or azacitidine plus venetoclax.","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-10-24","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia"],"enrollment":{"count":25,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"DSP107","otherNames":[],"type":"BIOLOGICAL"},{"name":"Azacitidine","otherNames":["Vidaza"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclexta, Venclyxto"],"type":"DRUG"}],"last_update":"2025-11-10","lead_sponsor":"Kahr Medical","official_title":"An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-04-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Adverse Events (AEs)","timeFrame":"Duration of the study, estimated to be 12 months"},{"measure":"Dose Limiting Toxicities (DLT)","timeFrame":"At the end of Treatment Cycle 2 (within 2 months of treatment initiation)"},{"measure":"Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)","timeFrame":"Within 6 months of treatment initiation"}],"references":[],"start_date":{"date":"2022-01-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies","url":"https://clinicaltrials.gov/study/NCT04937166"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04937166"}